DSM Pharmaceutical Products, the custom manufacturing and technology business for Royal DSM, has entered into a biologics contract manufacturing agreement with Paranta Biosciences of Melbourne, Australia.
The contract covers the process development and cGMP manufacture by DSM of Paranta's lead recombinant human protein for the treatment of respiratory diseases.
DSM’s new 70,000 square foot mammalian manufacturing facility will be located in Brisbane and is expected to be commissioned and operational in 2013.
This manufacturing plant is being constructed in collaboration with Biopharmaceuticals Australia (BPA), an industry-development company owned by the Queensland state government.
With this new manufacturing contract more of the drug development value chain will be retained locally and Australian biopharmaceutical developers will be able to locally manufacture new drug candidates to international standards in preclinical, clinical and commercial phases.
DSM Biologics president Karen King said the Brisbane facility is DSM's blueprint for its 'biologics plant of the future' for the production of biopharmaceuticals.
The deal has been welcomed by Biopharmaceutical Australia’s chief executive officer David Hughes.
"For Biopharmaceuticals Australia, DSM's signing-up Paranta for the new facility represents a key endorsement of the wisdom of the public sector investment in the project.”
He went on to say that “their vision of the ‘Biologics Plant of the Future’ matches ours and Australia’s first facility will have state-of-the-art capabilities.
“This is an important step for our industry,” Hughes added.
The partnering deal with DSM has been put together by BPA, and is currently project managing the final stages of construction of the new manufacturing facility in Brisbane.